These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 14976929)

  • 1. [Current issues in adjuvant hormone therapy of breast cancer].
    Semiglazov VF; Semiglazov VV
    Vopr Onkol; 2003; 49(6):771-5. PubMed ID: 14976929
    [No Abstract]   [Full Text] [Related]  

  • 2. Tamoxifen in early breast cancer.
    Arriagada R
    Lancet; 1998 Aug; 352(9125):403-4. PubMed ID: 9717953
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant endocrine therapy for premenopausal hormone receptor-positive breast cancer; much done, more to do.
    Higgins MJ; Wolf AC
    Oncology (Williston Park); 2009 Jan; 23(1):40, 42, 44. PubMed ID: 19283920
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
    J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
    Di Leo A; Buyse M
    J Clin Oncol; 2002 Apr; 20(7):1954-5. PubMed ID: 11919262
    [No Abstract]   [Full Text] [Related]  

  • 6. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB; Buzdar AU
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy for all patients with breast cancer?
    Lippman ME; Hayes DF
    J Natl Cancer Inst; 2001 Jan; 93(2):80-2. PubMed ID: 11208870
    [No Abstract]   [Full Text] [Related]  

  • 8. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
    Semilgazov VF; Manikhas AG; Semiglazov VV; Bozhok AA; Dashian GA; Ivanov VG; Paltuev RM; Vasil'ev AG; Shchedrin DE; Ermachenkova AM; Nikitina IV; Pen'kov KD; Bessonov AA; Tabagua TT; Kolar'kova VV
    Vopr Onkol; 2011; 57(5):567-77. PubMed ID: 22238925
    [No Abstract]   [Full Text] [Related]  

  • 9. Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
    Raina V
    Nat Clin Pract Oncol; 2004 Nov; 1(1):20-1. PubMed ID: 16264793
    [No Abstract]   [Full Text] [Related]  

  • 10. Meeting highlights: International consensus panel on the treatment of primary breast cancer.
    Love RR
    J Clin Oncol; 2002 Apr; 20(7):1955-6; author reply 1956-7. PubMed ID: 11919263
    [No Abstract]   [Full Text] [Related]  

  • 11. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: a randomized study.
    Gundersen S; Hannisdal E; Søreide JA; Skarstein A; Varhaug JE
    Breast Cancer Res Treat; 1995; 36(1):49-53. PubMed ID: 7579506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
    Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of randomized trials of systemic adjuvant therapy.
    Ravdin PM
    Cancer Treat Res; 2000; 103():157-81. PubMed ID: 10948446
    [No Abstract]   [Full Text] [Related]  

  • 15. Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer.
    Wolff AC; Davidson NE
    J Clin Oncol; 2006 Nov; 24(31):4949-51. PubMed ID: 17075110
    [No Abstract]   [Full Text] [Related]  

  • 16. [Estrogen and progesterone receptors in breast cancer].
    Sonoo H
    Nihon Rinsho; 2000 Apr; 58 Suppl():146-53. PubMed ID: 11025988
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting breast cancer with hormonal treatment options.
    Mellington TE; Fields MM
    Nurse Pract; 2008 May; 33(5):17-22; quiz 22-3. PubMed ID: 18458623
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
    Jordan VC; Morrow M
    J Natl Cancer Inst; 2003 May; 95(9):683-4; author reply 684-5. PubMed ID: 12734320
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
    Du XL
    J Natl Cancer Inst; 2003 May; 95(9):683; author reply 684-5. PubMed ID: 12734321
    [No Abstract]   [Full Text] [Related]  

  • 20. Tamoxifen: an enduring star.
    Veronesi U; Maisonneuve P; Decensi A
    J Natl Cancer Inst; 2007 Feb; 99(4):258-60. PubMed ID: 17312297
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.